

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for the securities of the Company.*



## **Link-Asia International MedTech Group Limited**

**環亞國際醫療科技集團有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1143)**

### **FURTHER EXTENSION OF LONG STOP DATE IN RELATION TO THE PLACING OF NEW SHARES UNDER GENERAL MANDATE**

Reference is made to the announcement of Link-Asia International MedTech Group Limited (the “**Company**”) dated 19 June 2023 in relation to the Placing of new Shares under General Mandate (the “**Announcement**”) and the announcement of the Company dated 10 July 2023 in relation to the extension of the Long Stop Date (the “**Extension Announcement**”). Unless otherwise stated, capitalised terms used herein shall have the same meanings as defined in the Announcement and the Extension Announcement.

As disclosed in the Extension Announcement, the Long Stop Date has been extended from 10 July 2023 to 31 July 2023 (or such later date as the Company and the Placing Agent may agree in writing) pursuant to the supplemental agreement (the “**First Supplemental Placing Agreement**”) to the Placing Agreement dated 10 July 2023.

As additional time is required for the Placing Agent to procure investors to subscribe for the Placing Shares, the Company and the Placing Agent entered into the second supplemental agreement to the Placing Agreement on 31 July 2023 (the “**Second Supplemental Placing Agreement**”) whereby the parties agreed to further extend the Long Stop Date from 31 July 2023 to 21 August 2023 (or such later date as the Company and the Placing Agent may agree in writing).

The Directors consider that the terms of the Second Supplemental Placing Agreement are on normal commercial terms and fair and reasonable and in the interests of the Company and the Shareholders as a whole.

Save and except for the change disclosed above, all other terms and conditions of the Placing Agreement (as amended and supplemented by the First Supplemental Placing Agreement and the Second Supplemental Placing Agreement) remain unchanged and continue to remain in full force and effect.

**Since the Completion is subject to the satisfaction of the conditions precedent as set out in the Placing Agreement, the Placing may or may not proceed. Shareholders and potential investors are reminded to exercise caution when dealing in the securities of the Company.**

On behalf of the Board  
**Link-Asia International MedTech Group Limited**  
**Lin Dailian**  
*Chairman and executive Director*

Hong Kong, 31 July 2023

*As at the date of this announcement, the Board comprises Mr. Lin Dailian (Chairman), Mr. Liu Zhiwei, Mr. Li Yinxiang, Ms. Lin Xiaoshan and Ms. Bian Sulan as executive Directors; Mr. Li Huiwu and Mr. Chak Chi Shing as independent non-executive Directors.*